We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
- Authors
Kim, Seok Jin; Yoon, Dok Hyun; Kang, Hye Jin; Hong, Jung Yong; Lee, Ho Sup; Oh, Sung Yong; Shin, Ho-Jin; Kong, Jee Hyun; Yi, Jun Ho; Sakamoto, Kana; Ko, Young Hyeh; Huh, Jooryung; Lee, Seung-Sook; Takeuchi, Kengo; Shin, Dong-Yeop; Suh, Cheolwon; Kim, Won Seog
- Abstract
<bold>Background: </bold>The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib.<bold>Methods: </bold>Relapsed or refractory patients with HL or PMBCL were eligible for this study, and JAK2 amplification was assessed by fluorescence in situ hybridization. Ruxolitinib was administered orally at a dose of 20 mg twice daily for a 28-day cycle. Treatment was continued for up to 16 cycles or until progressive disease or intolerability. The primary objective was to assess the overall disease control rate comprising complete response (CR), partial response (PR), or stable disease (SD).<bold>Results: </bold>We analyzed 13 HL patients and six PMBCL patients. All responders (one CR, five PR, and one SD) had HL whereas all cases of PMBCL progressed after first or second cycle. The disease control rate for HL was 54% (7/13) with median response duration of 5.6 months. JAK2 amplification was present in six of nine patients tested (four HL, two PMBCL), and three of these HL patients showed PR (n = 2) or SD (n = 1). None of the three HL patients shown to not have JAK2 amplification responded to ruxolitinib. Most treatment-related adverse events were grade 1 or 2 and manageable.<bold>Conclusions: </bold>Ruxolitinib has single-agent activity against HL but does not act against PMBCL with or without JAK2 amplification.<bold>Trial Registration: </bold>The study population was patients who had relapsed or refractory HL or PMBCL, and patients were registered for our pilot study after providing written informed consent between November 2013 and November 2015 (CilinicalTrials.gov: NCT01965119).
- Subjects
HODGKIN'S disease; FLUORESCENCE in situ hybridization; DIFFUSE large B-cell lymphomas; INFORMED consent (Medical law); TUMOR growth; PROTEIN metabolism; B cell lymphoma; DRUG therapy; CLINICAL trials; COMPARATIVE studies; GENE amplification; HETEROCYCLIC compounds; LONGITUDINAL method; RESEARCH methodology; MEDIASTINAL tumors; MEDICAL cooperation; PROTEINS; RESEARCH; PILOT projects; EVALUATION research; TREATMENT effectiveness; CHEMICAL inhibitors
- Publication
BMC Cancer, 2019, Vol 19, Issue 1, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-019-6303-z